Yesterday | MediLexicon
HER2-like And Basal-Like Genotype Breast Cancer Are More Likely To Respond To Chemotherapy
New data suggest that breast cancer patients with HER2- and basal-molecular subtypes are more likely to respond to neoadjuvant chemotherapy than patients with luminal-type molecular subtype characteristics.
Changing paradigms in the treatment of chronic lymphocytic leukemia
E-mail: kfoon@nvcancer.org Received 11 August 2009; Revised 16 October 2009; Accepted 4 November 2009; Published online 24 December 2009.
UR study reveals chemo's toxicity to brain, possible treatment
Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1. Published early online in the journal Cancer Investigation , the University of Rochester Medical Center study is relevant to the ...
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and...
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102 Export J Clin Oncol , Vol.
Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
MethodsWe studied 438 tumors from 710 premenopausal women with node-positive breast cancer who received cyclophosphamide, epirubicin, and 5-fluorouracil or cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in the randomized National Cancer Institute of Canada Clinical Trials Group Mammary 5 trial.
Rituxan (rituximab) is the first treatment to show improved overall...
Roche announced today at the 51st Meeting of the American Society of Hematology in New Orleans, LA that the pivotal Phase III study CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia survived their disease longer when treated with Rituxan compared to chemotherapy alone.
Mycophenolate mofetil is as efficacious as, but safer than,...
Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression Export Rheumatology In Rheumatology, Vol.
Roche reports positive Phase III results for MabThera/Rituxan
As Roche said at the 51st meeting of the American Society of Hematology , the trial showed that patients treated with the medicine and with chemotherapy lived longer than those treated with chemotherapy alone.
Genentech, Biogen Idec cancer drug rejected
SOUTH SAN FRANCISCO, Calif. The Food and Drug Administration has turned down a request by two biotech companies seeking approval for a drug as a treatment for chronic lymphocytic leukemia.
Capecitabine Linked to Benefit in Breast Cancer Patients
A chemotherapy regimen including capecitabine is associated with a lower risk of breast cancer recurrence compared to a combination of standard drugs, according to research published online Nov.
Acute Multiple Sclerosis Characterized by Extensive Mononuclear Phagocyte Infiltration
Immunohistochemical studies revealed extensive gliosis and mononuclear phagocyte infiltration with corresponding upregulation of proinflammatory cytokines .
Improved Recurrence-Free Survival With Capecitabine, But Increased Adverse Events
An article published Online First and in the December edition of The Lancet Oncology reports that addition of capecitabine to a standard chemotherapy regimen for breast cancer improves recurrence-free survival.
Early Changes in Functional Dynamic Magnetic Resonance Imaging...
Abstract 10.1158/1078-0432.CCR-07-4310 Dynamic contrast-enhanced magnetic resonance imaging allows noninvasive, measurements of tissue microvessel perfusion and permeability.
Protecting hair: Novel formulation halts chemotherapy-induced alopecia
Chemotherapy-induced alopecia is considered to be one of the most distressing adverse events resulting from chemotherapeutic treatment regimens, having serious psychosocial ramifications for the patient.
Mycophenolate mofetil and intravenous cyclophosphamide are similar as ...
Correspondence: Jai Radhakrishnan, Columbia University Medical Center, 622 W. 168th St., PH4124, New York, New York 10032, USA.
Different therapy for vasculitis reduces devastating side effect
We have all seen prescription drug commercials that end with a voice rapidly listing information about potential side effects and hazards.
Early detection of patients with poor risk diffuse large B-cell lymphoma.
More than 60% of patients with diffuse large B-cell lymphoma will be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone .
Modulation of cytochrome P450 activity: implications for cancer therapy.
Variability between individuals in the pharmacokinetics of cancer chemotherapy has important consequences in terms of therapeutic efficacy and safety.
New therapy for vasculitis will help patients avoid infertility and cancer
Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.
Date: Oct 16, 2009 a Categories: Campus News , Greek Life , News, Viagra tablets sale , Viagra in canada pfizer , Get viagra a By: Crissie Elrick Crissie Elrick Photo Editori 1 2 cmelrick@valdosta.edu Generally all antidepressants take review Cody suggested of nebulized morphine for Best way to use cialis although patients may of dyspnea from the.
Also on Topix